Key TakeawaysNovo Nordisk (NVO) has launched an unsolicited bid valued at up to $9 billion for obesity-drug developer Metsera (MTSR), aiming to outbid Pfizer's (PFE) existing agreement of up to $7.3 billion.Metsera's board has deemed Novo Nordisk's offer a "superior proposal," triggering a four-business-day window for Pfizer to renegotiate its terms, amidst Pfizer's accusations of antitrust violations and breach of contract.Novo Nordisk has vehemently denied Pfizer's claims, stating that Pfizer is "fundamen ...